EUVIMEDEUVIMED entdecken
Crossref

Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases

Pamela Trillo, Josè Sandoval, Dario Trapani, Eleonora Nicolò, Paola Zagami, Federica Giugliano, Paolo Tarantino, Grazia Vivanet, Liliana Ascione, Alex Friedlaender, Angela Esposito, Carmen Criscitiello und 1 weitere

European Journal of Cancer · 2023-05 · 185 · 119-130

DOI: 10.1016/j.ejca.2023.02.028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2023-05. Verfasst von Pamela Trillo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, 20141 Milan, Italy; Department of Oncology and Hematology, Un…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Breast Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Invasive lobular carcinoma (ILC) has unique clinical-biological features. Phenotypical differences between primary tumours (PTs) and metastases (M) have been described for invasive ductal carcinoma, but data on ILC are limited. METHODS: We retrospectively analysed patients with recurrent ILC from our institution from 2013 to 2020. We evaluated the discordance of the oestrogen receptor (ER), progesterone receptor (PgR) and HER2 between PT and M, to understand prognostic and therapeutic implications. RESULTS: Thirteen percent (n = 91) of all patients had ILC. We observed 15%, 44% and 5% of ER, PgR and HER2 status discordance between PT and M. ER/PgR discordance was related to receptor loss and HER2 mainly due to gain. PT presented a luminal-like phenotype (93%); 6% and 1% were triple-negative (TNBC) and HER2-positive. In M, there was an increase in TNBC (16%) and HER2-positive (5%). Metastasis-free survival and overall survival (OS) were different according to clinical phenotype, with poorer prognosis for HER2+ and TNBC (p 0.05). CONCLUSION: Our results suggest that phenotype switch after metastatic progression may be associated with patients' outcomes. Tumour biopsy in recurrent ILC could drive treatment decision-making, with prognostic implications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularBreast NeoplasmsHumansFemaleRetrospective StudiesErb-b2 Receptor Tyrosine KinasesNeoplasm Recurrence, LocalPrognosisReceptors, Progesterone

Stichwörter der Autor:innen

BCBreast cancerILCInvasive lobular carcinomaMetastasisPrimary tumourReceptor discordance

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, Progesterone

Autor:innen und Institutionen

  • Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, 20141 Milan, Italy; Department of Oncology and Hematology, University of Milan, 20122 Milan, Italy.
  • Unit of Population Epidemiology, Division and Department of Primary Care Medicine, 1205 Geneva University Hospitals, Geneva, Switzerland; Department of Oncology, Geneva University Hospitals, 1205 Geneva, Switzerland.
  • Breast Oncology Program, Dana-Farber Cancer Institute, 02115 Boston, USA; Harvard Medical School, 02115 Boston, USA.
  • Department of Oncology, Geneva University Hospitals, 1205 Geneva, Switzerland.
  • Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, 20141 Milan, Italy.
  • Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, 20141 Milan, Italy; Department of Oncology and Hematology, University of Milan, 20122 Milan, Italy. Electronic address: giuseppe.cu…

Förderung

  • Ministero della Salute

Zitieren

APA

Trillo, P., Sandoval, J., Trapani, D., Nicolò, E., Zagami, P., Giugliano, F., Tarantino, P., Vivanet, G., Ascione, L., Friedlaender, A., Esposito, A., Criscitiello, C., & Curigliano, G. (2023). Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases. European Journal of Cancer, 185, 119-130. https://doi.org/10.1016/j.ejca.2023.02.028

Vancouver

Trillo P, Sandoval J, Trapani D, Nicolò E, Zagami P, Giugliano F, et al. Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases. European Journal of Cancer. 2023;185:119-130. doi:10.1016/j.ejca.2023.02.028

BibTeX
@article{Trillo2023,
  author = {Trillo, Pamela and Sandoval, Josè and Trapani, Dario and Nicolò, Eleonora and Zagami, Paola and Giugliano, Federica and Tarantino, Paolo and Vivanet, Grazia and Ascione, Liliana and Friedlaender, Alex and Esposito, Angela and Criscitiello, Carmen and Curigliano, Giuseppe},
  title = {Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases},
  journal = {European Journal of Cancer},
  year = {2023},
  volume = {185},
  pages = {119--130},
  doi = {10.1016/j.ejca.2023.02.028}
}
Kostenlos starten →